Aventis’ proposed Ketek labeling
Aventis is adding a precaution to its proposed labeling for Ketek (telithromycin) following reports of exacerbation of symptoms in patients already diagnosed with myasthenia gravis being treated with the antibiotic. The company is responding to FDA requests for "additional analyses and information" outlined in the agency's Jan. 24 "approvable" letter for Ketek (1"The Pink Sheet" Feb. 10, In Brief). Ten cases of exacerbated myasthenia gravis have been reported; Aventis is also sending "Dear Healthcare Professional" letters...
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.